Načítá se...
Immunotherapeutic Mechanisms of Anti-CD20 Monoclonal Antibodies
The anti-CD20, B cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, e.g. NK cell-mediated killing, may lead to substantial decreas...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2660201/ https://ncbi.nlm.nih.gov/pubmed/18585457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coi.2008.05.011 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|